GMRE vs ARE Stock Comparison: AI Score, Valuation, Performance and Upside
ARE is the dominant, large-scale leader in life science real estate with premier lab campuses in top innovation hubs, while GMRE is a much smaller, niche medical office REIT with a more modest growth profile. The comparison highlights very different scales and sub-sectors within healthcare-adjacent real estate.
GMRE vs ARE contrasts a small-cap medical office REIT against the dominant, large-scale leader in life science laboratory real estate.
GMRE and ARE are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to smaller-scale, niche medical office real estate
- See value in Global Medical REIT's growth potential from a smaller base
- Are comfortable with higher relative leverage and tenant concentration risk
- Want exposure to the dominant leader in life science laboratory real estate
- Value Alexandria's premier locations in top biotech innovation clusters
- Believe life science real estate demand will recover from near-term oversupply pressures
| Metric | GMRE | ARE |
|---|---|---|
| AI scorei | N/A | 25.5 |
| AI ranki | N/A | #2600 |
| Latest closei | N/A | $46.00 |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GMRE | ARE |
|---|---|---|
| 1Y ago | N/A | $8.45K (-15.5%) started 2025-11-05 |
| 5Y ago | N/A | $2.96K (-70.4%) started 2021-11-08 |
| 10Y ago | N/A | $7.87K (-21.3%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | GMRE | ARE |
|---|---|---|
| Market capi | N/A | $8.8B |
| Trailing P/Ei | N/A | 102.99 |
| Forward P/Ei | N/A | -63.14 |
| Price/Salesi | 3.30 | N/A |
| EV/Revenuei | N/A | 8.88 |
| Analyst targeti | N/A | $53.00 |
| Target upsidei | N/A | +3.64% |
| Metric | GMRE | ARE |
|---|---|---|
| Revenue growthi | N/A | -11.90% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | +47.35% |
| Operating margini | N/A | 17.28% |
| Profit margini | N/A | -36.08% |
| ROIC proxyi | N/A | -4.08% |
| Return on equityi | N/A | -4.08% |
| Dividend yieldi | N/A | 5.81% |
| Payout ratioi | N/A | 689.47% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.01 | 1.17 |
| Debt/equityi | N/A | 68.67 |
| Current ratioi | N/A | 2.35 |
| Quick ratioi | N/A | 1.98 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GMRE | ARE |
|---|---|---|---|
| 1Y | Growthi | N/A | -15.55% |
| CAGRi | N/A | -15.57% | |
| Volatilityi | N/A | 45.96% | |
| Sharpe ratioi | N/A | -0.24 | |
| Sortino ratioi | N/A | -0.34 | |
| Max drawdowni | N/A | 33.14% | |
| Current drawdowni | N/A | 22.94% | |
| Avg drawdowni | N/A | 15.37% | |
| Ulcer Indexi | N/A | 17.14% | |
| Max daily dropi | N/A | 11.30% | |
| Max wkly dropi | N/A | 15.86% | |
| 5Y | Growthi | N/A | -74.42% |
| CAGRi | N/A | -23.90% | |
| Volatilityi | N/A | 35.44% | |
| Sharpe ratioi | N/A | -0.72 | |
| Sortino ratioi | N/A | -0.97 | |
| Max drawdowni | N/A | 79.55% | |
| Current drawdowni | N/A | 76.43% | |
| Avg drawdowni | N/A | 46.66% | |
| Ulcer Indexi | N/A | 50.57% | |
| Max daily dropi | N/A | 19.17% | |
| Max wkly dropi | N/A | 28.48% | |
| 10Y | Growthi | N/A | -42.68% |
| CAGRi | N/A | -5.42% | |
| Volatilityi | N/A | 30.41% | |
| Sharpe ratioi | N/A | -0.18 | |
| Sortino ratioi | N/A | -0.24 | |
| Max drawdowni | N/A | 79.55% | |
| Current drawdowni | N/A | 76.43% | |
| Avg drawdowni | N/A | 25.35% | |
| Ulcer Indexi | N/A | 35.94% | |
| Max daily dropi | N/A | 19.17% | |
| Max wkly dropi | N/A | 28.48% |
| Category | GMRE | ARE |
|---|---|---|
| Company | Global Medical REIT Inc. | Alexandria Real Estate Equities, Inc. |
| Sector | Real Estate - Healthcare REIT | Real Estate |
| Industry | N/A | REIT - Office |
| Core business | Global Medical REIT is a smaller healthcare REIT that owns medical office buildings and other healthcare-related real estate, leasing properties to physician groups and healthcare systems under long-term net leases. | Alexandria Real Estate Equities is the leading life science real estate REIT, developing and owning lab and office campuses clustered in major life science innovation hubs like Boston, San Francisco, and San Diego. |
| Investor focus | Investors track Global Medical REIT's acquisition pace and cap rates, tenant credit quality, and dividend coverage given its smaller scale relative to larger healthcare REIT peers. | Investors track Alexandria's life science lab leasing demand, development pipeline progress, and occupancy trends amid a period of elevated new life science supply in some markets. |
- Focused, niche strategy targeting outpatient medical office properties
- Smaller scale provides more room for percentage-based portfolio growth
- Net lease structure with healthcare tenants provides relatively stable, predictable cash flow
- Dominant position in premier life science real estate clusters with high barriers to entry
- Strong, long-standing relationships with leading biotech and pharmaceutical tenants
- Large, well-located development pipeline supports long-term growth
- Much smaller scale than larger healthcare REIT peers limits capital cost and diversification advantages
- Higher relative leverage and tighter dividend coverage than larger, better-capitalized peers
- Tenant concentration risk given smaller overall portfolio size
- Life science real estate has faced near-term oversupply pressure in some major markets
- Biotech tenant funding environment directly affects lab space demand
- Larger scale and higher valuation require sustained execution to justify
Compare more than two at a time
This page is a fixed writeup on GMRE and ARE. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside GMRE and ARE, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.